Atorvastatin disrupts primary human brain microvascular endothelial cell functions via prenylation‐dependent mitochondrial inhibition and oxidative stress

Abstract

Primary human brain microvascular endothelial cell (HBMEC) is the major component of the blood–brain barrier (BBB). Atorvastatin, a HMG‐CoA reductase inhibitor, is a cholesterol‐lowering drug commonly used to reduce the risk for cardiovascular disease. Numerous studies have reported the pleiotropic effects of atorvastatin on endothelial cells, but the findings are controversial and inconclusive. In addition, little is known about the biological effects of atorvastatin on HBMEC. In this work, we demonstrate that atorvastatin at micromolar but not nanomolar concentrations induces dysfunctions of a number of HBMEC events, including differentiation into capillary network, migration and growth but not cell adhesion. We further show that the inhibitory effects of atorvastatin on HBMEC are independent of angiogenesis stimulators. Atorvastatin induces HBMEC apoptosis even in the presence of vascular endothelial growth factor (VEGF) and serum. Mechanism studies indicate that atorvastatin at micromolar concentration leads to protein prenylation inhibition, mitochondrial dysfunction and thereby subsequent oxidative stress and damage in HBMEC. Rescue experiments confirm that atorvastatin inhibits HBMEC functions via prenylation‐dependent mitochondrial inhibition. Our work reveals the inhibitory effects of atorvastatin on HBMEC and suggests the possible negative influence of atorvastatin in blood–brain barrier.

Paraquat-induced cholesterol biosynthesis proteins dysregulation in human brain microvascular endothelial cells

“…In addition, a recent study of Tan et al . reported a reduction in cholesterol level, as well as a mitochondrial dysfunction on HBMECs by atorvastatin, which is an inhibitor of cholesterol production 64 . Our study has also highlighted a significant decrease of cellular cholesterol in a time- and dose-dependent manner.…”

Standardized study of atorvastatin possible osteoarthritis disease‐modifying effect in a rat model of osteoarthritis

“…Statins combat cardiovascular disease, and they reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, which is a key enzyme that catalyzes the synthesis of a precursor of cholesterol and nonsterol isoprenoids (e.g., mevalonate) [3]. Atorvastatin may have important roles in OA due to its cholesterol-lowering effects as altered lipid hemostasis can share in OA development by causing subchondral bone ischemia, thereby increasing OA progression [4].…”